| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
IBC 293 targets the human orphan G protein-coupled receptor GPR109B (HM74/HCAR3), which is expressed in adipocytes. It acts as a highly selective agonist of this receptor, with an EC50 of 400 nM. It shows higher selectivity for GPR109B over GPR109A. By activating GPR109B, IBC 293 inhibits forskolin- and isoproterenol-stimulated cAMP accumulation in CHO cells expressing GPR109B and in human adipocytes. This receptor is involved in the regulation of lipolysis and other metabolic processes.
|
|---|---|
| ln Vitro |
IBC 293 is a selective agonist of GPR109B with an EC50 of 400 nM. It inhibits forskolin- and isoproterenol-stimulated cAMP accumulation in CHO cells expressing GPR109B and in human adipocytes. Its activity has been confirmed in various in vitro assays. It is a cell-permeable compound that can activate GPR109B-mediated signaling in cellular models. It shows higher selectivity for GPR109B over GPR109A.
|
| ln Vivo |
IBC 293 is used in research on cardiac metabolic diseases. Its ability to activate GPR109B and modulate cAMP signaling suggests potential therapeutic applications in metabolic disorders. However, detailed in vivo efficacy data in animal models is limited. The compound is primarily used as a research tool to study the GPR109B signaling pathway and its role in metabolism.
|
| Enzyme Assay |
The primary in vitro assay for IBC 293 is a cAMP accumulation assay using cells expressing GPR109B, such as CHO cells or human adipocytes. Cells are treated with the compound, and the levels of cAMP are measured using ELISA or a homogeneous time-resolved fluorescence (HTRF) assay. The EC50 of 400 nM is determined from dose-response curves. Radioligand binding assays can also be used to measure its affinity for GPR109B.
|
| Cell Assay |
In vitro cellular experiments for IBC 293 involve treating cells expressing GPR109B, such as CHO cells or human adipocytes, with the compound and measuring its effects on cAMP accumulation. The inhibition of forskolin- or isoproterenol-stimulated cAMP production is assessed. Its effects on downstream signaling pathways, such as MAPK or AKT, can also be evaluated.
|
| Animal Protocol |
In vivo animal experiments for IBC 293 are not extensively detailed in the available literature. As a GPR109B agonist, it could be evaluated in animal models of metabolic diseases, such as obesity, diabetes, or dyslipidemia. Its effects on lipid metabolism, glucose homeostasis, and inflammation would be assessed. Its pharmacokinetic properties and safety profile would also be evaluated.
|
| ADME/Pharmacokinetics |
IBC 293 has a molecular weight of 205.2 g/mol and a molecular formula of C10H11N3O2. It is a cell-permeable small molecule. It is soluble in DMSO. It is typically used as a research reagent and is stored as a powder at -20°C for long-term stability. Its purity is typically ≥98%.
|
| Toxicity/Toxicokinetics |
IBC 293 is a research compound that is not intended for human use. Its toxicological profile is not extensively characterized in the available literature. As with all research chemicals, standard safety precautions should be followed when handling. Its safety would need to be established for therapeutic applications.
|
| References | |
| Additional Infomation |
1-Prop-2-yl-5-benzotriazole carboxylic acid is a type of benzotriazole compound.
IBC 293 is a cell-permeable, highly selective agonist of the human orphan G protein-coupled receptor GPR109B (HM74/HCAR3) with an EC50 of 400 nM. It shows higher selectivity for GPR109B over GPR109A. IBC 293 inhibits forskolin- and isoproterenol-stimulated cAMP accumulation in cells expressing GPR109B and in human adipocytes. It is used in research on cardiac metabolic diseases. |
| Molecular Formula |
C10H11N3O2
|
|---|---|
| Molecular Weight |
205.22
|
| Exact Mass |
205.085
|
| CAS # |
306935-41-1
|
| PubChem CID |
2736690
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
413.9±18.0 °C at 760 mmHg
|
| Melting Point |
229-230ºC
|
| Flash Point |
204.1±21.2 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.655
|
| LogP |
2.05
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
15
|
| Complexity |
257
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RUTVRAJKELSHCC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H11N3O2/c1-6(2)13-9-4-3-7(10(14)15)5-8(9)11-12-13/h3-6H,1-2H3,(H,14,15)
|
| Chemical Name |
1-propan-2-ylbenzotriazole-5-carboxylic acid
|
| Synonyms |
IBC-293; IBC293; IBC 293
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~487.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8728 mL | 24.3641 mL | 48.7282 mL | |
| 5 mM | 0.9746 mL | 4.8728 mL | 9.7456 mL | |
| 10 mM | 0.4873 mL | 2.4364 mL | 4.8728 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
